Successfully reported this slideshow.
We use your LinkedIn profile and activity data to personalize ads and to show you more relevant ads. You can change your ad preferences anytime.

Open Source Pharma: What is the problem with drug R&D

968 views

Published on

Presentation given by Bernard Munos at the Open Source Pharma Conference at Rockefeller Foundation Bellagio Center, July 2014.

Bernard Munos Bio:
http://www.opensourcepharma.net/participants/bernard-munos

Conference Agenda (see Day 1, Session 1):
http://www.opensourcepharma.net/agenda.html

Published in: Science
  • Be the first to comment

  • Be the first to like this

Open Source Pharma: What is the problem with drug R&D

  1. 1. What’s the Problem with Drug R&D? Bellagio, Italy, July 15-18, 2014 #opensourcepharma
  2. 2. What is the problem? • Too little innovation • Too much mediocre innovation • Unaffordable innovation • Rests on non-predictive science  Erratic  Driven by black swans  High-risk  High prices  No Moore’s Law… only Eroom’s Law! InnoThink
  3. 3. Driven by unattractive “attractors” High risk High return High R&D investment Industry concentration Industry fragmentation Low risk Low return Low R&D investment InnoThink
  4. 4. What else? • Inadequate leadership for much of past decade  Changing in companies with leaders willing and able to deal with the challenge (e.g., jnj, gsk, sny, nvs, roche, bmy, bay, azn) • Underperforming research model • ½ Big Pharma = High-priced generic industry • Ambivalent about change • Change difficult… outcomes uncertain… but those that do not reform, will be outperformed InnoThink
  5. 5. Alternatives: How can we outperform the status quo? InnoThink • Open-source drug R&D (e.g., OSDD, OSM) • Crowdsourcing (e.g., Innocentive) • Drug repurposing (e.g., NIH, disease foundations, “biotechs”) • Public-private partnerships (e.g., DNDi, MMV) • Networked innovation (e.g, ANDI/WHO; J&J) • Virtual companies (many “biotechs”; GSK) • Forced disruption (DARPA) • Precompetitive collaboration (Consortia-Pedia) • Biological modeling (Sage, Dassault)
  6. 6. More thoughts… InnoThink • Let’s increase the supply of drugs… not manage the scarcity • We are on the cusp of a hyper-innovation age… but it will involve mostly different players • Some industries cannot be reformed… they can only be disrupted… and disruption always comes from the outside • Innovation should be plentiful… much of the information is free… tools are widely available… craft is non longer proprietary • Crowdfunding and microfinancing will meet a growing share of drug discovery financing needs • IP is only a problem because there is too little of it that’s any good… scarcity drives up value
  7. 7. Last thoughts… • We are witnessing 3 transformations at once  The transformation of biology  The transformation of research tools and methods  The transformation of medicine • All three are driven by data… that spells change • The expertise in data analysis does not reside in pharma • Smart phones changed the world in < 7 years… We can change pharma yet in this decade InnoThink
  8. 8. 8

×